PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business Phase I dose escalation study with pamlectabart tismanitin (HDP-101) in multiple myeloma completed Dose escalation study has started at the recommended Phase II dose (RP2D) and is proceeding as planned Amendment of existing agreement with Health [ … ]

PRESS RELEASE Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026 All agenda items approved by a large majority 2026 Annual General Meeting elects Jack Yefei Ling as new member of the Supervisory Board Ladenburg, Germany, 23 June 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developin [ … ]

PRESS RELEASE Heidelberg Pharma Announces Change in Executive Board CFO Walter Miller is leaving Heidelberg Pharma at the end of April Supervisory Board appoints Peter Willinger as a new Chief Financial Officer, effective 1 May 2026 Ladenburg, Germany, 17 April 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing [ … ]

PRESS RELEASE Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital Heidelberg Pharma is eligible to receive USD 20 million upfront funded by Soleus Capital, subject to closing conditions USD 25 million to be funded by Soleus Capital upon FDA approval of Telix Pharmaceu [ … ]

PRESS RELEASE Heidelberg Pharma Received Development Milestone Payment from Partner Takeda Ladenburg, Germany, 29 January 2026 - Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreemen [ … ]